

East Asia Esophageal Cancer Forum in Tokyo

“New era of esophageal cancer treatment”



DATE: 3rd/MAR/2024(Sun)

Venue: National Cancer Center, Tsukiji 5-1-1, Chuo-ku, Tokyo

Organizer: Japan Esophageal Society

Co-Organizer: National Cancer Center Hospital



Registration

On-Site:

<https://docs.google.com/forms/d/e/1FAIpQLSfHRADXtWtNN0ptyKOyKR-3u-EGB79bOswPBIKcCMwwL2xmVA/viewform?vc=0&c=0&w=1&flr=0>

Webinar:

https://us02web.zoom.us/webinar/register/WN_8qtjF7TFTf6uk39-jggg_A




East Asia Esophageal Cancer Forum in Tokyo

“New era of esophageal cancer treatment”



9:00	Opening remarks	Hiroya Takeuchi
SESSION 1: Moderator: Manabu Muto, I-Chen Wu Progress in Multimodal Treatment for Early stage Esophageal Cancer		
9:10	Indications and treatment outcomes for T1a-MM and T1b esophageal squamous cell carcinoma in Japan	Dr. Yoshinobu Yamamoto
9:30	ER+ selective CRT for stage I esophageal squamous cell carcinoma: JCOG0508	Dr. Keiko Minashi
9:50	Minimally invasive treatment strategies for Stage I esophageal cancer Current status in Taiwan	Prof. I-Chen Wu
10:10	Treatment strategies for re-examination of Stage I esophageal cancer - ER, ER+CRT or ER+Salvage Surgery	Prof. Philip Chiu
Session 2: Moderator: Masayuki Watanabe, Jang-Ming Lee New Question of surgical treatment for Esophageal Cancer		
10:30	A randomized controlled phase III trial comparing thoracoscopic esophagectomy and open esophagectomy for thoracic esophageal cancer, JCOG1409 (MONET trial)	Prof. Hiroya Takeuchi
10:50	Preoperative immune therapy for esophageal cancer	Prof. Lijie Tan
11:10	Not all esophagectomies are created equal: Impact of the extent of LND in the era of neoadjuvant therapy	Prof. Dae Joon Kim
11:30	Perioperative immune therapy for esophageal squamous cell carcinoma	Dr. Shun Yamamoto
Lunch		
Session 3: Moderator: Ken Kato, Chih Hung Hsu New Multimodality therapy for Advanced Esophageal Cancer		
12:30	Exploring novel immunotherapy in advanced esophageal squamous cell carcinoma: is targeting-TIGIT an answer?	Prof. Chih Hung Hsu
12:50	Current advance of the systemic chemotherapy for esophageal squamous cell carcinoma.	Prof. Min Hee Hong
13:10	Oligometastatic disease project for ESCC	Dr. Motoo Nomura
13:30	A randomized controlled phase III study comparing 2-weekly docetaxel, cisplatin and 5-FU (bDCF) with cisplatin and 5-FU (CF) in patients with metastatic or recurrent esophageal cancer: JCOG1314 (MIRACLE)	Dr. Takahiro Tsushima
13:50	Closing remarks	Ken Kato
14:00	Group Photo	All

Faculty and Presenters



Hiroya Takeuchi,
Department of Surgery,
Hamamatsu University School of Medicine,
Japan



Manabu Muto,
Department of Clinical Oncology,
Kyoto University Hospital,
Japan




I-Chen Wu,
Professor of College of Medicine,
Kaohsiung Medical University,
Taiwan



Yoshinobu Yamamoto,
Department of Gastrointestinal Oncology,
Hyogo Cancer Center,
Japan



Keiko Minashi,
Department of Gastroenterology,
Chiba Cancer Center,
Japan



Philip Chiu,
Faculty of Medicine,
The Chinese University of Hong Kong,
Hong Kong



Masayuki Watanabe,
Department of Gastroenterological Surgery,
Cancer Institute Hospital,
Japan



Jang Ming Lee,
Department of Surgery,
National Taiwan University College of Medicine,
Taiwan

Faculty and Presenters



Li-Jie Tan,
Division of Thoracic Surgery,
Zhong Shan Hospital, Fudan University,
China



Dae Joon Kim,
Department of Thoracic & Cardiovascular
Surgery, Yonsei University Medical College
Korea



Shun Yamamoto,
Department of Head and Neck, Esophageal
Medical Oncology,
National Cancer Center Hospital, Japan



Ken Kato,
Department of Head and Neck, Esophageal
Medical Oncology,
National Cancer Center Hospital, Japan



Chih-Hung Hsu,
Department of Oncology, National Taiwan
University College of Medicine,
Taiwan



Min Hee Hong,
Department of Internal Medicine,
Yonsei University College of Medicine,
Korea



Motoo Nomura,
Department of Clinical Oncology,
Kyoto University Hospital,
Japan



Takahiro Tsushima,
Division of Gastrointestinal Oncology,
Shizuoka Cancer Center Hospital,
Japan